Role of the p53 family in stabilizing the genome and preventing polyploidization

Advances in Experimental Medicine and Biology

Volumn 675, Issue , 2010, Pages 73-91

  Talos, Flaminia ^b   Moll, Ute M ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P53; PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; CYCLIN DEPENDENT KINASE; CYCLIN E;

ANEUPLOIDY; ARTICLE; BINDING SITE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; GENE OVEREXPRESSION; GENETIC STABILITY; GENOME; GENOTOXICITY; HETEROZYGOSITY; HISTONE MODIFICATION; HUMAN; MISSENSE MUTATION; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; T LYMPHOCYTE; ANIMAL; CELL DIVISION; GENETICS; GENOMIC INSTABILITY; HUMAN CHROMOSOME; METABOLISM; NEOPLASM; REVIEW; CELL ACTIVATION; CELL SURFACE; DNA DAMAGE CHECKPOINT; DOWN REGULATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; GENETIC ASSOCIATION; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; P73 GENE; S PHASE CELL CYCLE CHECKPOINT; TETRAPLOIDY; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; ANIMALS; CELL DIVISION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DNA-BINDING PROTEINS; G2 PHASE; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; POLYPLOIDY; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77955895723     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6199-0_5     Document Type: Article

References (131)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358(6381):15-6.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88(3):323-31. (Pubitemid 27131374)
3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408(6810):307-10.
4. Arai M, Shimizu S, Imai Y et al. Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer 1997; 70(4):390-5. (Pubitemid 27107264)
5. Bressac B, Kew M, Wands J et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350(6317):429-31. (Pubitemid 21912246)
6. Chen SJ, Wang Q, Tong JH et al. Monoallelic deletions of the P53 gene in Chinese patients with chronic myelogenous leukemia in blastic crisis. Nouv Rev Fr Hematol 1991; 33(6):481-4.
7. Fagin JA, Matsuo K, Karmakar A et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91(1):179-84. (Pubitemid 23037270)
8. Oda H, Zhang S, Tsurutani N et al. Loss of p53 is an early event in induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res 1997; 57(4):646-50. (Pubitemid 27085647)
9. Hung J, Mims B, Lozano G et al. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat 1999; 14(3):216-21. (Pubitemid 29407262)
10. Law JC, Strong LC, Chidambaram A et al. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 1991; 51(23 Pt 1):6385-7.
11. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250(4985):1233-8. (Pubitemid 120031831)
12. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356(6366):215-21.
13. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994; 8(1):66-9.
14. Donehower LA, Harvey M, Vogel H et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14(1):16-22.
15. Harvey M, Sands AT, Weiss RS et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993; 8(9):2457-67. (Pubitemid 23252375)
16. Purdie CA, Harrison DJ, Peter A et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994; 9(2):603-9.
17. Elson A, Deng C, Campos-Torres J et al. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 1995; 11(1):181-90.
18. Blyth K, Terry A, O'Hara M et al. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: Contrasting effects of homozygous and heterozygous p53 loss. Oncogene 1995; 10(9):1717-23.
19. Rong S, Donehower LA, Hansen MF et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 1995; 55(9):1963-70.
20. Donehower LA, Godley LA, Aldaz CM et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 1995; 9(7):882-95.
21. Thompson TC, Park SH, Timme TL et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995; 10(5):869-79.
22. Olive KP, Tuveson DA, Ruhe ZC et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119(6):847-60. (Pubitemid 40017690)
23. Lang GA, Iwakuma T, Suh YA et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119(6):861-72. (Pubitemid 40017691)
24. Wahl GM, Linke SP, Paulson TG et al. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv 1997; 29:183-219. (Pubitemid 27262247)
25. Agarwal ML, Agarwal A, Taylor WR et al. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92(18):8493-7.
26. Smith KA, Agarwal ML, Chernov MV et al. Regulation and mechanisms of gene amplification. Philos Trans R Soc Lond B Biol Sci 1995; 347(1319):49-56.
27. Stewart N, Hicks GG, Paraskevas F et al. Evidence for a second cell cycle block at G2/M by p53. Oncogene 1995; 10(1):109-15.
28. Cross SM, Sanchez CA, Morgan CA et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267(5202):1353-6.
29. Fukasawa K, Choi T, Kuriyama R et al. Abnormal centrosome amplification in the absence of p53. Science 1996; 271(5256):1744-7. (Pubitemid 26102826)
30. Almasan A, Linke SP, Paulson TG et al. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 1995; 14(1):59-73.
31. Almasan A, Yin Y, Kelly RE et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes and apoptosis. Proc Natl Acad Sci USA 1995; 92(12):5436-40.
32. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15(17):2177-96. (Pubitemid 32843830)
33. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 2004; 14(1):11-6. (Pubitemid 38173005)
34. Sengupta S, Linke SP, Pedeux R et al. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 2003; 22(5):1210-22. (Pubitemid 36313604)
35. Sengupta S, Shimamoto A, Koshiji M et al. Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 2005; 24(10):1738-48. (Pubitemid 40461130)
36. Tibbetts RS, Brumbaugh KM, Williams JM et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999; 13(2):152-7. (Pubitemid 29061945)
37. Tibbetts RS, Cortez D, Brumbaugh KM et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000; 14(23):2989-3002.
38. Squires S, Coates JA, Goldberg M et al. p53 prevents the accumulation of double-strand DNA breaks at stalled-replication forks induced by UV in human cells. Cell Cycle 2004; 3(12):1543-57. (Pubitemid 40521408)
39. Schwartz D, Rotter V. p53-dependent cell cycle control: Response to genotoxic stress. Semin Cancer Biol 1998; 8(5):325-36. (Pubitemid 29131354)
40. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20(15):1803-15. (Pubitemid 32458690)
41. Kastan MB, Onyekwere O, Sidransky D et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51(23 Pt 1):6304-11.
42. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6(1):44-55. (Pubitemid 40064898)
43. Di Leonardo A, Khan SH, Linke SP et al. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997; 57(6):1013-9. (Pubitemid 27138591)
44. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998; 18(2):1055-64. (Pubitemid 28063440)
45. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 1995; 92(19):8876-80.
46. Frank KM, Sekiguchi JM, Seidl KJ et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998; 396(6707):173-7. (Pubitemid 28523619)
47. Gao Y, Ferguson DO, Xie W et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 2000; 404(6780):897-900. (Pubitemid 30230344)
48. Gao Y, Sun Y, Frank KM et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95(7):891-902. (Pubitemid 29019042)
49. Mummenbrauer T, Janus F, Muller B et al. p53 Protein exhibits 3'-to-5' exonuclease activity. Cell 1996; 85(7):1089-99. (Pubitemid 26235279)
50. Fortunato EA, Spector DH. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol 1998; 72(3):2033-9. (Pubitemid 28100757)
51. Sturzbecher HW, Donzelmann B, Henning W et al. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 1996; 15(8):1992-2002. (Pubitemid 26119232)
52. Linke SP, Sengupta S, Khabie N et al. p53 interacts with hRAD51 and hRAD54 and directly modulates homologous recombination. Cancer Res 2003; 63(10):2596-605. (Pubitemid 36605201)
53. Bertrand P, Saintigny Y, Lopez BS. p53's double life: Transactivation-independent repression of homologous recombination. Trends Genet 2004; 20(6):235-43. (Pubitemid 38625681)
54. Bishop AJ, Hollander MC, Kosaras B et al. Atm-, p53- and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development. Cancer Res 2003; 63(17):5335-43. (Pubitemid 37139848)
55. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408(6811):433-9.
56. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5(10):773-85. (Pubitemid 41400777)
57. Margolis RL, Lohez OD, Andreassen PR. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003; 88(4):673-83. (Pubitemid 36258817)
58. Shi Q, King RW. Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005; 437(7061):1038-42. (Pubitemid 41486986)
59. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17(2):157-62. (Pubitemid 46551722)
60. Pellman D. Cell biology: Aneuploidy and cancer. Nature 2007; 446(7131):38-9. (Pubitemid 46348036)
61. Fujiwara T, Bandi M, Nitta M et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437(7061):1043-7. (Pubitemid 41486987)
62. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 2004; 5(1):45-54. (Pubitemid 38089840)
63. Comai L. The advantages and disadvantages of being polyploid. Nat Rev Genet 2005; 6(11):836-46.
64. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 2003; 120(1):117-30. (Pubitemid 35462100)
65. Gupta S. Hepatic polyploidy and liver growth control. Semin Cancer Biol 2000; 10(3):161-71.
66. Vliegen HW, Eulderink F, Bruschke AV et al. Polyploidy of myocyte nuclei in pressure overloaded human hearts: A flow cytometric study in left and right ventricular myocardium. Am J Cardiovasc Pathol 1995; 5(1):27-31.
67. Oberringer M, Lothschutz D, Jennewein M et al. Centrosome multiplication accompanies a transient clustering of polyploid cells during tissue repair. Mol Cell Biol Res Commun 1999; 2(3):190-6. (Pubitemid 129533217)
68. Notterman D, Young S, Wainger B et al. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity. Oncogene 1998; 17(21):2743-51. (Pubitemid 28554233)
69. Mortimer RK. Radiobiological and genetic studies on a polyploid series (haploid to hexaploid) of Saccharomyces cerevisiae. Radiat Res 1958; 9(3):312-26.
70. Kato N, Lam E. Chromatin of endoreduplicated pavement cells has greater range of movement than that of diploid guard cells in Arabidopsis thaliana. J Cell Sci 2003; 116(Pt 11):2195-201. (Pubitemid 36722366)
71. Verstraeten VL, Broers JL, Ramaekers FC et al. The nuclear envelope, a key structure in cellular integrity and gene expression. Curr Med Chem 2007; 14(11):1231-48. (Pubitemid 46739324)
72. Mayer VW, Aguilera A. High levels of chromosome instability in polyploids of Saccharomyces cerevisiae. Mutat Res 1990; 231(2):177-86. (Pubitemid 20252550)
73. Molnar M, Sipiczki M. Polyploidy in the haplontic yeast Schizosaccharomyces pombe: Construction and analysis of strains. Curr Genet 1993; 24(1-2):45-52. (Pubitemid 23240890)
74. Hau PM, Siu WY, Wong N et al. Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells. FEBS letters 2006; 580(19):4727-36. (Pubitemid 44189395)
75. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53cells. EMBO J 2002; 21(4):483-92. (Pubitemid 34174030)
76. Ring D, Hubble R, Kirschner M. Mitosis in a cell with multiple centrioles. J Cell Biol 1982; 94(3):549-56. (Pubitemid 13241186)
77. Andreassen PR, Lohez OD, Lacroix FB et al. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001; 12(5):1315-28. (Pubitemid 33044413)
78. Margolis RL. Tetraploidy and tumor development. Cancer Cell 2005; 8(5):353-4. (Pubitemid 41579830)
79. Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 2005; 331(3):694-700. (Pubitemid 40615499)
80. Uetake Y, Sluder G. Cell cycle progression after cleavage failure: Mammalian somatic cells do not possess a "tetraploidy checkpoint". J Cell Biol 2004; 165(5):609-15. (Pubitemid 38765762)
81. Wong C, Stearns T. Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number and cytokinesis failure. BMC Cell Biol 2005; 6(1):6.
82. Borel F, Lohez OD, Lacroix FB et al. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci USA 2002; 99(15):9819-24. (Pubitemid 34831131)
83. Attardi LD, Donehower LA. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 2005; 576(1-2):4-21. (Pubitemid 40982679)
84. Frank KM, Sharpless NE, Gao Y et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 2000; 5(6):993-1002.
85. Lee Y, Barnes DE, Lindahl T et al. Defective neurogenesis resulting from DNA ligase IV deficiency requires Atm. Genes Dev 2000; 14(20):2576-80.
86. Sugawara N, Paques F, Colaiacovo M et al. Role of Saccharomyces cerevisiae Msh2 and Msh3 repair proteins in double-strand break-induced recombination. Proc Natl Acad Sci USA 1997; 94(17):9214-9. (Pubitemid 27357809)
87. Cranston A, Bocker T, Reitmair A et al. Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet 1997; 17(1):114-8. (Pubitemid 27377544)
88. Strathdee G, Sansom OJ, Sim A et al. A role for mismatch repair in control of DNA ploidy following DNA damage. Oncogene 2001; 20(15):1923-7. (Pubitemid 32458702)
89. Aylon Y, Michael D, Shmueli A et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20(19):2687-700. (Pubitemid 44498379)
90. Zhu J, Jiang J, Zhou W et al. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998; 58(22):5061-5. (Pubitemid 28521161)
91. Zaika A, Irwin M, Sansome C et al. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001; 276(14):11310-6. (Pubitemid 38089320)
92. Yang A, Walker N, Bronson R et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404(6773):99-103. (Pubitemid 30143141)
93. Mills AA, Zheng B, Wang XJ et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398(6729):708-13. (Pubitemid 29197649)
94. Flores ER, Sengupta S, Miller JB et al. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7(4):363-73. (Pubitemid 40544653)
95. Perez-Losada J, Wu D, DelRosario R et al. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 2005; 24(35):5521-4. (Pubitemid 43080095)
96. Keyes WM, Wu Y, Vogel H et al. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005; 19(17):1986-99. (Pubitemid 41247957)
97. Nozaki M, Tada M, Kashiwazaki H et al. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol 2001; 11(3):296-305. (Pubitemid 32494572)
98. Moll UM, Erster S, Zaika A. p53, p63 and p73-solos, alliances and feuds among family members. Biochim Biophys Acta 2001; 1552(2):47-59. (Pubitemid 34124130)
99. Levrero M, De Laurenzi V, Costanzo A et al. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113 (Pt 10):1661-70. (Pubitemid 30333115)
100. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2(8):605-15. (Pubitemid 37328927)
101. Melino G, Lu X, Gasco M et al. Functional regulation of p73 and p63: Development and cancer. Trends Biochem Sci 2003; 28(12):663-70. (Pubitemid 37500901)
102. Concin N, Becker K, Slade N et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64(7):2449-60. (Pubitemid 38523899)
103. Massion PP, Taflan PM, Jamshedur Rahman SM et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63(21):7113-21. (Pubitemid 37413448)
104. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25(1):47-54. (Pubitemid 30257035)
105. Costanzo A, Merlo P, Pediconi N et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002; 9(1):175-86. (Pubitemid 34127781)
106. Vayssade M, Haddada H, Faridoni-Laurens L et al. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116(6):860-9. (Pubitemid 41209191)
107. Moll UM. The Role of p63 and p73 in tumor formation and progression: Coming of age toward clinical usefulness. Commentary re: F Koga et al, Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9:5501-5507;
108. P Puig et al. p73 Expression in human normal and tumor tissues: Loss of p73alpha expression is associated with tumor progression in bladder Cancer. Clin Cancer Res 2003; 9:5642-5651 (Pubitemid 37499486)
109. Clin Cancer Res 2003; 9(15):5437-41.
110. Gong JG, Costanzo A, Yang HQ et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399(6738):806-9. (Pubitemid 29293179)
111. Lissy NA, Davis PK, Irwin M et al. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 2000; 407(6804):642-5.
112. Herranz M, Santos J, Salido E et al. Mouse p73 gene maps to the distal part of chromosome 4 and might be involved in the progression of gamma-radiation-induced T-cell lymphomas. Cancer Res 1999; 59(9):2068-71. (Pubitemid 29217666)
113. Flores ER, Tsai KY, Crowley D et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416(6880):560-4. (Pubitemid 34288861)
114. Talos F, Nemajerova A, Flores ER et al. p73 Suppresses Polyploidy and Aneuploidy in the Absence of Functional p53. Mol Cell 2007; 27(4):647-59. (Pubitemid 47238632)
115. Watanabe A, Inokuchi K, Yamaguchi H et al. Near-triploidy and near-tetraploidy in hematological malignancies and mutation of the p53 gene. Clin Lab Haematol 2004; 26(1):25-30. (Pubitemid 38241477)
116. Feijoo C, Hall-Jackson C, Wu R et al. Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154(5):913-23. (Pubitemid 34286172)
117. Blain SW, Scher HI, Cordon-Cardo C et al. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3(2):111-5. (Pubitemid 37443384)
118. Cheng M, Olivier P, Diehl JA et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18(6):1571-83. (Pubitemid 29127070)
119. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78(1):67-74. (Pubitemid 24228301)
120. Vassilev LT, Tovar C, Chen S et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 2006; 103(28):10660-5. (Pubitemid 44078033)
121. Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19(9):2069-81. (Pubitemid 30237582)
122. Kossatz U, Dietrich N, Zender L et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 2004; 18(21):2602-7. (Pubitemid 39453099)
123. Garcia P, Frampton J, Ballester A et al. Ectopic expression of cyclin E allows non-endomitotic megakaryoblastic K562 cells to establish rereplication cycles. Oncogene 2000; 19(14):1820-33. (Pubitemid 30200988)
124. Matsumura I, Tanaka H, Kawasaki A et al. Increased D-type cyclin expression together with decreased cdc2 activity confers megakaryocytic differentiation of a human thrombopoietin-dependent hematopoietic cell line. J Biol Chem 2000; 275(8):5553-9. (Pubitemid 30115191)
125. Vogel C, Kienitz A, Hofmann I et al. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004; 23(41):6845-53. (Pubitemid 39279985)
126. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3(5):421-9. (Pubitemid 38340288)
127. Blint E, Phillips AC, Kozlov S et al. Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA 2002; 99(6):3529-34.
128. Nozell S, Chen X. p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family. Oncogene 2002; 21(8):1285-94. (Pubitemid 34185245)
129. Avni D, Yang H, Martelli F et al. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell 2003; 12(3):735-46. (Pubitemid 37222493)
130. Bosco EE, Mayhew CN, Hennigan RF et al. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 2004; 32(1):25-34. (Pubitemid 38228601)
131. Gonzalo S, Garcia-Cao M, Fraga MF et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol 2005; 7(4):420-8. (Pubitemid 40533133)